InvestSMART

4DMedical Limited (ASX:4DX)

ALERT: Price-sensitive ASX Announcement for 4DX
Current share price for 4DX : $3.970 2.43 (157.79%)+
Announcement
Release
5 Nov 2025 10:30AM
Price at Release
$1.540
Full Release
download
Summary
4DMedical Limited (4DX) responded to an ASX Query Letter regarding its financial report for the year ended June 30, 2025. The response detailed the company's compliance with accounting standards and the steps taken to address the auditor's qualified opinion, which stemmed from insufficient evidence for the carrying value of goodwill and intangible assets. The company highlighted the acquisition of Imbio, which added significant intangible assets, and outlined its intention to support future revenue growth through commercial activities and partnerships to obtain an unqualified audit opinion. The board confirmed that financial records were properly maintained and compliant with ASX Listing Rules.
Key Points
  • 4DMedical Limited (4DX) acquired Imbio in December 2023, adding $68.9m of intangible assets.
  • 4DX's financial records and statements were confirmed to be compliant with accounting standards by the board.
  • The auditor issued an unmodified report for 4DX's consolidated financials ended June 30, 2024, but a qualified opinion for 2025 due to insufficient evidence supporting goodwill and intangible assets.
  • 4DX plans to obtain an unmodified audit opinion in future financials by supporting revenue growth through signed contracts and partnerships.
  • The board confirmed compliance with ASX Listing Rules, particularly Listing Rule 3.1.
  • Evidence provided to auditors included management's forecasts, a discounted cash flow model, and discussions with the board and auditors.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.